MYO7A_HUMAN,D483G,0.443,-,-,-
MYO7A_HUMAN,D483N,0.211,-,-,-
MYO7A_HUMAN,T520L,0.798,Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.16 | P = 0.05), ELME000052|ELME000147|ELME000336|PS00008,-
MYO7A_HUMAN,T522A,0.090,-,-,-
MYO7A_HUMAN,T523H,0.824,Altered Metal binding (Pr = 0.20 | P = 0.03), ELME000052|ELME000147|PS00008,-
MYO7A_HUMAN,K533R,0.189,-,-,-
MYO7A_HUMAN,A536R,0.243,-,-,-
MYO7A_HUMAN,A536S,0.071,-,-,-
MYO7A_HUMAN,I539F,0.454,-,-,-
MYO7A_HUMAN,N544S,0.157,-,-,-
MYO7A_HUMAN,I551H,0.936,Altered Metal binding (Pr = 0.79 | P = 7.3e-04); Altered Stability (Pr = 0.31 | P = 5.0e-03); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Allosteric site at H553 (Pr = 0.22 | P = 0.02); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), None,-
MYO7A_HUMAN,N552Q,0.288,-,-,-
MYO7A_HUMAN,H582Y,0.418,-,-,-
MYO7A_HUMAN,I592L,0.279,-,-,-
MYO7A_HUMAN,A595T,0.217,-,-,-
MYO7A_HUMAN,A601S,0.164,-,-,-
MYO7A_HUMAN,S607W,0.629,Loss of Phosphorylation at S607 (Pr = 0.70 | P = 1.2e-03); Loss of Intrinsic disorder (Pr = 0.51 | P = 5.8e-03); Loss of ADP-ribosylation at R604 (Pr = 0.21 | P = 0.03); Loss of Ubiquitylation at K605 (Pr = 0.15 | P = 0.05), ELME000012|ELME000053|ELME000061|ELME000100|ELME000108|ELME000136|ELME000159|ELME000173|ELME000278|PS00004,-
MYO7A_HUMAN,S612C,0.394,-,-,-
MYO7A_HUMAN,L646R,0.732,Gain of Acetylation at K642 (Pr = 0.29 | P = 4.6e-03); Gain of Allosteric site at F647 (Pr = 0.23 | P = 0.02), ELME000146|ELME000233|ELME000313,-
MYO7A_HUMAN,H650P,0.680,Gain of Allosteric site at F647 (Pr = 0.26 | P = 7.5e-03); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000106|ELME000313,-
MYO7A_HUMAN,V653I,0.350,-,-,-
MYO7A_HUMAN,E663K,0.929,Altered Disordered interface (Pr = 0.45 | P = 2.1e-03); Altered Metal binding (Pr = 0.35 | P = 2.1e-03); Gain of Strand (Pr = 0.27 | P = 0.03); Altered DNA binding (Pr = 0.25 | P = 6.4e-03); Gain of Acetylation at E663 (Pr = 0.22 | P = 0.02); Loss of Allosteric site at Y658 (Pr = 0.20 | P = 0.04), ELME000052|PS00008,-
MYO7A_HUMAN,D700N,0.606,, ELME000156|PS00008,-
MYO7A_HUMAN,T704P,0.843,, ELME000062|ELME000336,-
MYO7A_HUMAN,Q706R,0.451,-,-,-
MYO7A_HUMAN,K723R,0.330,-,-,-
MYO7A_HUMAN,E739K,0.602,, ELME000047|ELME000100|ELME000108|ELME000333,-
MYO7A_HUMAN,A743E,0.721,Altered Coiled coil (Pr = 0.24 | P = 0.01); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000052|ELME000146|ELME000173,-
MYO7A_HUMAN,N763S,0.300,-,-,-
MYO7A_HUMAN,Y787C,0.809,Altered Disordered interface (Pr = 0.26 | P = 0.02), ELME000120|ELME000134|ELME000233,-
MYO7A_HUMAN,Y787F,0.399,-,-,-
MYO7A_HUMAN,G788E,0.154,-,-,-
MYO7A_HUMAN,M790I,0.387,-,-,-
MYO7A_HUMAN,R791Q,0.468,-,-,-
MYO7A_HUMAN,A799V,0.654,Altered Coiled coil (Pr = 0.32 | P = 9.7e-03); Altered DNA binding (Pr = 0.27 | P = 4.0e-03); Altered Disordered interface (Pr = 0.26 | P = 0.01), None,-
MYO7A_HUMAN,L800W,0.634,Altered Disordered interface (Pr = 0.49 | P = 1.5e-03); Altered Stability (Pr = 0.26 | P = 7.5e-03); Altered DNA binding (Pr = 0.25 | P = 8.9e-03), ELME000336,-
MYO7A_HUMAN,S803A,0.257,-,-,-
MYO7A_HUMAN,R804G,0.530,Altered Disordered interface (Pr = 0.49 | P = 3.0e-03); Altered DNA binding (Pr = 0.30 | P = 1.8e-03); Altered Stability (Pr = 0.15 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04), ELME000085|ELME000102|ELME000336|PS00005,-
MYO7A_HUMAN,K805G,0.498,-,-,-
MYO7A_HUMAN,L806M,0.250,-,-,-
MYO7A_HUMAN,Y810P,0.908,Altered Disordered interface (Pr = 0.37 | P = 8.2e-03); Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Coiled coil (Pr = 0.14 | P = 0.03), None,-
MYO7A_HUMAN,Y810S,0.830,Gain of Intrinsic disorder (Pr = 0.44 | P = 4.6e-03); Altered Disordered interface (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.18 | P = 0.03); Altered Coiled coil (Pr = 0.13 | P = 0.04), None,-
MYO7A_HUMAN,R811G,0.239,-,-,-
MYO7A_HUMAN,R816H,0.209,-,-,-
MYO7A_HUMAN,R816L,0.428,-,-,-
MYO7A_HUMAN,I817L,0.212,-,-,-
MYO7A_HUMAN,Q819E,0.084,-,-,-
MYO7A_HUMAN,Q821R,0.782,Altered Coiled coil (Pr = 0.19 | P = 0.02), ELME000012|ELME000134|ELME000137,-
MYO7A_HUMAN,K831R,0.116,-,-,-
MYO7A_HUMAN,L864Q,0.166,-,-,-
MYO7A_HUMAN,R866S,0.547,Altered Disordered interface (Pr = 0.49 | P = 2.9e-03); Altered Coiled coil (Pr = 0.21 | P = 0.02), ELME000182,-
MYO7A_HUMAN,K871R,0.205,-,-,-
MYO7A_HUMAN,M872L,0.108,-,-,-
MYO7A_HUMAN,K888R,0.150,-,-,-
MYO7A_HUMAN,D908S,0.361,-,-,-
MYO7A_HUMAN,R921Q,0.139,-,-,-
MYO7A_HUMAN,H934R,0.115,-,-,-
MYO7A_HUMAN,K945R,0.135,-,-,-
MYO7A_HUMAN,R972Q,0.085,-,-,-
MYO7A_HUMAN,V978L,0.090,-,-,-
MYO7A_HUMAN,E998D,0.302,-,-,-
MYO7A_HUMAN,S1016T,0.065,-,-,-
MYO7A_HUMAN,D1030S,0.319,-,-,-
MYO7A_HUMAN,A1089T,0.381,-,-,-
MYO7A_HUMAN,G1092C,0.412,-,-,-
MYO7A_HUMAN,G1094S,0.197,-,-,-
MYO7A_HUMAN,L1098V,0.081,-,-,-
MYO7A_HUMAN,K1128V,0.604,Loss of Intrinsic disorder (Pr = 0.47 | P = 0.01); Loss of Acetylation at K1128 (Pr = 0.29 | P = 4.6e-03), ELME000100|ELME000108|ELME000147|ELME000233|PS00005,-
MYO7A_HUMAN,D1132Q,0.365,-,-,-
MYO7A_HUMAN,G1133A,0.389,-,-,-
MYO7A_HUMAN,I1158V,0.349,-,-,-
MYO7A_HUMAN,A1203S,0.313,-,-,-
MYO7A_HUMAN,F1235S,0.662,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered DNA binding (Pr = 0.26 | P = 5.7e-03); Altered Stability (Pr = 0.25 | P = 8.0e-03); Altered Transmembrane protein (Pr = 0.09 | P = 0.05); Gain of N-linked glycosylation at N1237 (Pr = 0.03 | P = 0.03), ELME000008|ELME000053|ELME000061|ELME000062|ELME000065|ELME000336|PS00004,-
MYO7A_HUMAN,N1285D,0.259,-,-,-
MYO7A_HUMAN,K1294R,0.215,-,-,-
MYO7A_HUMAN,I1303V,0.525,Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000083|ELME000120|ELME000182|ELME000233,-
MYO7A_HUMAN,A1340T,0.811,Altered Transmembrane protein (Pr = 0.29 | P = 2.1e-04); Gain of Pyrrolidone carboxylic acid at Q1336 (Pr = 0.08 | P = 0.02), ELME000136|ELME000153|ELME000159,-
MYO7A_HUMAN,T1352A,0.712,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Metal binding (Pr = 0.27 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 6.7e-03); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000053|ELME000136|ELME000146|ELME000155|ELME000159|ELME000289|ELME000358,-
MYO7A_HUMAN,P1357S,0.711,Gain of Relative solvent accessibility (Pr = 0.38 | P = 5.7e-04); Altered Metal binding (Pr = 0.29 | P = 0.02); Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.5e-03), ELME000064|ELME000173|ELME000239|PS00006,-
MYO7A_HUMAN,S1358A,0.135,-,-,-
MYO7A_HUMAN,I1417V,0.336,-,-,-
MYO7A_HUMAN,D1419A,0.703,Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000081|ELME000182|ELME000254|ELME000322,-
MYO7A_HUMAN,K1426R,0.217,-,-,-
MYO7A_HUMAN,D1450E,0.230,-,-,-
MYO7A_HUMAN,S1460N,0.049,-,-,-
MYO7A_HUMAN,F1479C,0.673,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Sulfation at Y1477 (Pr = 0.01 | P = 0.04), ELME000085|ELME000155,-
MYO7A_HUMAN,S1483T,0.265,-,-,-
MYO7A_HUMAN,M1517L,0.352,-,-,-
MYO7A_HUMAN,C1525F,0.846,Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Disulfide linkage at C1525 (Pr = 0.10 | P = 0.05), ELME000197|ELME000233,-
MYO7A_HUMAN,W1528S,0.378,-,-,-
MYO7A_HUMAN,G1537D,0.615,, PS00006,-
MYO7A_HUMAN,A1540E,0.282,-,-,-
MYO7A_HUMAN,A1540V,0.135,-,-,-
MYO7A_HUMAN,A1551D,0.364,-,-,-
MYO7A_HUMAN,A1551S,0.120,-,-,-
MYO7A_HUMAN,T1565M,0.103,-,-,-
MYO7A_HUMAN,A1587S,0.524,Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.23 | P = 0.02); Altered Transmembrane protein (Pr = 0.17 | P = 0.01); Gain of GPI-anchor amidation at N1586 (Pr = 0.02 | P = 0.02), ELME000063|ELME000064|ELME000336|PS00006,-
MYO7A_HUMAN,P1615S,0.341,-,-,-
MYO7A_HUMAN,E1621D,0.338,-,-,-
MYO7A_HUMAN,S1626G,0.443,-,-,-
